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Background: The use of biological samples in research raises a number of ethical issues in relation to consent,
storage, export, benefit sharing and re-use of samples. Participant perspectives have been explored in North
America and Europe, with only a few studies reported in Africa. The amount of research being conducted in Africa
is growing exponentially with volumes of biological samples being exported from the African continent. In order to
investigate the perspectives of African research participants, we conducted a study at research sites in the Western
Cape and Gauteng, South Africa.
Methods: Data were collected using a semi-structured questionnaire that captured both quantitative and
qualitative information at 6 research sites in South Africa. Interviews were conducted in English and Afrikaans. Data
were analysed both quantitatively and qualitatively.
Results: Our study indicates that while the majority of participants were supportive of providing samples for
research, serious concerns were voiced about future use, benefit sharing and export of samples. While researchers
view the provision of biosamples as a donation, participants believe that they still have ownership rights and are
therefore in favour of benefit sharing. Almost half of the participants expressed a desire to be re-contacted for
consent for future use of their samples. Interesting opinions were expressed with respect to export of samples.
Conclusions: Eliciting participant perspectives is an important part of community engagement in research
involving biological sample collection, export, storage and future use. A tiered consent process appears to be more
acceptable to participants in this study. Eliciting opinions of researchers and research ethics committee (REC)
members would contribute multiple perspectives. Further research is required to interrogate the concept of
ownership and the consent process in research involving biological samples.Background
Biological sample availability creates important opportu-
nities for researchers to advance medical science and
contribute to collective good [1,2]. However several eth-
ical, legal and social issues co-exist [3]. Research Ethics
Committees (RECs) globally have a mandate to protect
research participant interests such as confidentiality,
ownership, export, storage and secondary use of sam-
ples (individual good) with specific consent, regulations* Correspondence: km@sun.ac.za
1Centre for Medical Ethics and Law, Department of Medicine, Faculty of
Health Sciences, Stellenbosch University, Stellenbosch, South Africa
Full list of author information is available at the end of the article
© 2014 Moodley et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand policies but implementation of these policies differs
from one REC to another [4]. Researchers (unable to pre-
dict future use of samples due to scientific advances) pre-
fer a broad general form of consent to advance scientific
research and promote the collective good [1,5-9]. This
divergence of perspectives creates tension between RECs
that promote individual benefit and researchers who sup-
port collective benefit. Recently the tension has been exa-
cerbated by participant groups instituting litigation for
improper use of biospecimens - Havasupai Indian Tribe
Case [10] and other groups requesting return of speci-
mens - Yanamamo Tribe Case [11].al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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should begin with an exploration of participant expecta-
tions [10]. This is an important first step in discerning the
complexity of the debate. Several studies have investigated
participants’ preferences around the world - Egypt [12],
Asia [9] Scotland [13], Sweden [14,15], Canada [2,16],
United States [17], United Kingdom [18], Uganda [19] and
the Netherlands [20]. In South Africa, however, such a
process of public engagement has not occurred.
Debate should however be bidirectional with patholo-
gists and researchers also actively engaged on consent
for use of biological specimens. This process is important
for fostering mutual understanding between researchers
and participants and informing research ethics guidelines.
Pathologists have an important contribution to make, as
they are generally the custodians of biobanks and other
stores of biological samples [8]. Pathologists and resear-
chers share a common goal in terms of scientific research
and the advancement of scientific knowledge [1], but
hold a variety of views relating to the use of biological
specimens [5-7,21].
There is generally strong support for broad consent as
it is sometimes practically difficult to re-contact and
re-consent participants [7,22]. Some believe that it is
unethical not to store samples and conduct previously
unforeseen future studies, and that, since research par-
ticipants donate specimens, there is no need for external
control on what research is conducted on them as society
will ultimately benefit [22]. There is a school of thought
that supports the use of research using biological samples
donated to generate patents and profits that should not be
shared with participants [23-25]. And of course, the con-
trary view is held as well [26].
Internationally RECs differ in terms of their consent
requirements for use of biological samples and are criti-
cised for their lack of consistency in policy development
and enforcement [4]. In South Africa there is signi-
ficant variance in the composition and functioning of
RECs [27]. The existing 33 RECs registered with the
National Health Research Ethics Council (NHREC) cur-
rently are not equally capacitated and hence differ in
terms of their agendas, financing, resources and ethics
capacity training.
Southern Africa is regarded as fertile ground for a
wide range of research endeavours due to the enormous
burden of infectious disease in the region, highly skilled
medical researchers and large numbers of treatment
naïve patients [28,29]. South Africa is positioned at the
epicenter of the HIV pandemic and HIV research as well
as HIV biobanking is flourishing scientifically. There are
currently 1390 clinical trials registered on the South Afri-
can Clinical Trials Register hosted by the Department of
Health. Three years ago (2010) there were 946 trials regis-
tered [30]. This indicates a significant growth ofclinical trial research over the past 3 years. South Africa
(SA) is home to hundreds of research projects involving
biospecimen collection, analysis, storage and future use.
Exportation of samples to developed countries occurs
frequently.
To date, apart from a small study conducted on 20 re-
search participants at a single site, there has been very
little empirical research published examining the ethical
aspects of participant perspectives related to biospe-
cimen use in research in SA [31]. This timely study has
employed empirical research to elucidate perspectives
on biospecimen use in research in SA with a view to
informing guideline development, research ethics delib-
eration and legislation in this controversial research area.
The Human Tissues Act No 65 of 1983 has been re-
placed by new legislation in the National Health Act No
61 of 2003 dealing with use of human tissue samples,
biobanking, import and export of samples. There are
gaps in some of this legislation with respect to export of
samples, informed consent from participants and mater-
ial transfer agreements. The National Health Research
Ethics Council (NHREC) in SA is involved with the de-
velopment of guidelines for the collection, use, storage
and export of biological samples. These guidelines aim
to address gaps in legislation and elaborate on ethical
concerns more specifically. Findings from this study will
therefore impact timeously on policy development.
We are aware of two reported research studies that
used quantitative methods to investigate the perspec-
tives of African research participants regarding sample
storage and re-use, in Egypt [12] and Uganda [19]. The
Ugandan study (n = 343) found that a large majority
(95%) of participants would consent to their sample be-
ing re-used without additional consent, subject to ap-
proval by an Institutional Review Board (IRB). On the
other hand, the study in Egypt (n = 600) found that just
under half (44.3%) of the participants felt that consent
forms should include a separate section relating to
storage and future use of samples and data. To our know-
ledge, apart from a recent publication on biological sam-
ple use amongst 20 participants with Tuberculosis at a
single study site in South Africa [31], a focus group study
on biobanking in Nigeria amongst lay persons [32] and
a broader study on consent for genetic and genomic
research in Ghana [33], no other qualitative research stu-
dies have been reported in Africa. Considering the con-
textual complexity of these issues and the vast cultural
and geographical diversity on the African continent, we
believe it is of paramount importance to seek the views of
South African research participants on these issues. Our
study aimed to provide an exploration into these issues,
specifically seeking to qualitatively explore the views
of research participants on sample storage, export and
future use.
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This study was conducted over a 10 month period
from September 2011 to June 2012. We sampled 200
participants in the Western Cape and Gauteng (100
participants at each location) in order to capture as
many different perspectives as possible, given the di-
versity of populations in South Africa. Research partic-
ipants who had experience with research, the consent
process and biological samples were recruited from aca-
demic research units attached to public hospitals and pri-
vate research centres (6 research sites: 4 in the Western
Cape and 2 in Pretoria, Gauteng). Principal investigators
at the 6 clinical trial sites provided permission for the con-
duct of this sub-study. The participants had already pro-
vided consent to participate in the parent study.
Investigators on the parent study then approached partici-
pants to inform them about our sub-study. Those who
were interested in participating in the sub-study agreed to
interviews. We re-consented the participants specifically
for our biological samples sub-study. In total 200 semi-
structured questionnaires were completed by research as-
sistants during interviews in participants’ language of
choice – with data recorded in English. Question-
naires included demographic details and study specific
questions which focussed on perceptions of choice in pro-
viding samples, religious and cultural concerns related to
biological samples, storage export and consent related to
future use of samples. Explanations of biological sam-
ples and research ethics committees were provided be-
fore the related question was posed.
Interviews were conducted in English and Afrikaans
by the same interviewer at each site. Interviews were re-
corded and transcribed verbatim. Coding was conducted
by two researchers, in consultation with a third resear-
cher on the team. Initial coding of the data generated
themes, which were included in a second round of cod-
ing [34]. All members of the research team discussed the
coding of the data and assisted with establishing rela-
tionships between themes and constructing hierarchies.
Data analysis was conducted quantitatively and qualita-
tively. Approval was obtained from the Stellenbosch
University Health Research Ethics Committee (Ref N11/
07/227) as well as from the University of Pretoria Re-
search Ethics Committee (Ref s190/2011). All partici-
pants in this study consented voluntarily.
Results
In total 212 participants were approached to participate
in this biological samples study and 200/212 agreed
yielding a response rate of 94%.
The average age of the participants was 48 years, ran-
ging from 18 to 81 years. The majority of participants
(148/200 = 74%) were female. Most participants (81%)
had received a high school education (grade 8 to 12).Some (10.5%) had only received primary school educa-
tion. A few participants had not received any schooling
(2%) and a minority of participants had received tertiary
education (6.5%). Participants belonged to various reli-
gious denominations with the majority being Christian
(92.5%). The main home language of participants was
as follows: Afrikaans (41%), Xhosa (17%) and English
(14%). Most participants were able to read a newspaper
in English (87.5%) or Afrikaans (63%) and all partici-
pants were happy to conduct the interview in English or
Afrikaans.
While most participants (155/200 = 77.5%) felt they
had a choice in terms of providing samples for the re-
search project in which they were enrolled, as expressed
in the following responses:
I wanted to give [blood] because it was for a good
reason to help others.
I gave [blood] willingly for my own good.
41/200 (20.5%) indicated that they had no choice as
implied by the responses below:
They just said they have to take my blood.
The doctor just said I need a sample for this or that.
I was instructed to give the sample.
Storage of samples
Participants were asked how they felt about the possibil-
ity that their specimens could be stored after the initial
round of tests had been conducted. Most research par-
ticipants (155/200 = 77.5%) were comfortable with the
idea of sample storage. The most commonly cited reason
was that once the sample had been donated, they would
have no use for it and storage would not affect them.
However, 24/200 (12%) indicated that they would want
reasons for storage and would want to give permission
for storage:
It’s my blood so I would want to know where and why
it is being stored.
I would like to be informed if they want to store my
blood.
Future use of specimens and consent
Despite most participants voicing no objection to sto-
rage of their samples, almost half the sample (99/200)
(49.5%) indicated that they would want to be contacted
each time the sample was re-used. Even after the option
of a research ethics committee consenting on their be-
half was explained in detail, participants were not in
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want to be re-contacted to give consent, the other half
would allow a REC to consent on their behalf.
Export of specimens
While most participants (151/200 = 75%) did not object
to exportation of samples, 25/200 (10%) expressed strong
concerns and objections. These participants expressed
their concerns as follows:
Some countries would maybe use it for satanic rituals.
Not to the African countries. You hear a lot of stories
like they use the blood for their cultural things.
As long as it’s not Zimbabwe. They're going to mix
my blood with Mugabe.
[Blood must be used] only in Africa. I don’t want it to
go out of Africa.
[Blood] must not be taken to the United States,
European countries and UK.
As long as it’s not Israel – Israel is an open enemy of
the Muslim community.
[Not] Somalia because its far away. I don’t want my
samples going very far.
Benefit sharing
A substantial proportion of participants in this survey
(39.5%) indicated that they would mind if researchers or
research organisations generated profits from the re-
search in which they were involved. Of this subgroup,
34/79 (43%) expressed a desire for a share of the profits
while 45/79 (56%) indicated that they would be very un-
happy. A further 19.5% of participants would not mind if
profits were generated provided that research was con-
ducted for a good cause.
They must give me a portion of the profit because it
is my blood.
It’s funny because the company is using my child’s
blood. They must share the money.
I will sue them because I feel it’s a criminal offence
Would be unhappy - how can they make a profit?
Discussion
The empirical data generated by our study reflects inte-
resting participant perspectives on sample storage, ex-
port, re-use and benefit sharing in the research process.
Underlying many of these perspectives is the concept ofownership of biological samples. Although participants
indicated support for sample collection and storage, which
is consistent with existing literature [32,33,35-37], they
also expressed strong views about storage and future use,
export and benefit sharing.
Our data suggest that only half the participants were
in favour of a one-time broad consent procedure when
donating samples for storage and re-use, while half felt
that re-consent should be sought for future studies and
that an REC could not decide on their behalf. This is
in stark contrast to the findings of Wendler et al. in
Uganda, who reported that 95% of participants would be
happy not to be re-contacted, as long as the re-use was
approved by an Institutional Review Board. Similarly,
Chen and Pentz found that most participants would
authorize unlimited future research [36,37]. Our findings
are similar to the Abou Zeid study in Egypt where 44.3%
of the 600 participants surveyed preferred consent options
regarding storage and 39% of this subsection desired the
consent option for future research to be restricted to the
illness under study. Likewise, the study by Igbe et al. in
Nigeria revealed that half the participants interviewed
were in favour of broad consent, while 25% favoured
restricted consent and 25% preferred a tiered consent
process. Given participant perspectives on future use
of samples in African settings, it is important to allow
participants to express their choice regarding consent
for secondary use of samples.
The Declaration of Helsinki [38] makes provision for
consent by a research ethics committee in paragraph 25:
For medical research using identifiable human
material or data, physicians must normally seek
consent for the collection, analysis, storage and/or
re-use. There may be situations where consent would
be impossible or impractical to obtain for such
research or would pose a threat to the validity of the
research. In such situations the research may be done
only after consideration and approval of a research
ethics committee.
Half our participants did not support such substituted
decision making. This finding would suggest that relying
on ethics committees to make re-use decisions can be
challenging in a community where the focus of partici-
pants’ trust is more specifically on actual researchers
than the REC itself [31]. It is possible that education of
participants about the role of RECs has the potential to
change this perception.
Similar to the study by Van Schalkwyk, 19.5% of par-
ticipants had no desire to share in profits if research was
conducted for a good cause [31]. However, 39.5% of par-
ticipants would mind if a profit was made. Of this sub-
group, 43% expressed a desire for a share of the profits
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than the Abou-Zeid study where 32.8% of participants
desired a share in any commercial profits [12]. This un-
derstanding of benefit sharing is a matter for concern
given that most consent forms relating to biological sam-
ple collection and genetic testing contain a paragraph that
indicates the following:
“Discoveries made with your DNA samples may
be patented by us and the university. These patents
may be sold or licensed, which could give a
company the sole right to make and sell products
or offer testing based on discovery. Royalties may
be paid to us, the university and the sponsor. It is
not our intent to share any of these possible
royalties with you.” [39].
Despite signing consent forms with a similar provision,
research participants appear not to fully comprehend
this limitation in terms of benefit sharing. For partici-
pants, benefit sharing could range from monetary returns,
to access to interventions and/or health care. The Dec-
laration of Helsinki encourages comprehensive benefit
sharing that is not limited to access to experimental
interventions:
 33. At the conclusion of the study, patients
entered into the study are entitled to be
informed about the outcome of the study and to
share any benefits that result from it, for
example, access to interventions identified as
beneficial in the study or to other appropriate
care or benefits.
The disconnect between what consent documents may
indicate, what Helsinki aspires towards and what partici-
pants actually expect needs to be carefully considered by
researchers and REC members alike.
While most participants expressed a sense of comfort
with exportation of samples from South Africa, strong
views emerged from 10% of respondents. These views
reflected a sense of discomfort with respect to expor-
tation of samples to other African countries as well
as to developed countries like the United States, Europe
and the United Kingdom. Similar views were expressed in
the Abou-Zeid study where 62% of participants expressed
their desire to export samples but only to other Arab
countries [12]. This issue reflects the potential for further
research and has implications for the wording of consent
forms where exportation of samples is discussed.
Finally, the concept of ownership of samples is a fun-
damental question that needs to be explored further.
While some participants discussed samples in the con-
text of a donation, many still retained use of the phrase“my blood” or “my child’s blood”. Participants in our
survey clearly expressed a sense of “ownership” of their
samples, as is implied by the repeated references to “my
blood”. This is contrary to the concept of donation of
samples in the context of research. Such perspectives
were related to the need to be re-contacted for consent
for future use and with respect to benefit sharing. It is
therefore critical that ownership issues are clarified with
communities as part of the community engagement
process and with research participants during recruit-
ment and that this concept is revisited and reinforced
during the consent process.
This study is not without limitations. Conducting re-
search of this nature is challenging in several respects.
In order to gain access to research participants on actual
study sites, it is important that research teams do not
feel threatened. We had to clarify that the purpose of
our study was not to assess the consent process at the
sites but rather to obtain participant views on biolo-
gical sample collection. As such, site selection was li-
mited to those sites where the principal investigator
did not object to our line of questioning. We selected
research participants at those sites where biological
sample collection was part of the research process. How-
ever, we were not able to compare the information given
in consent forms at various sites regarding sample collec-
tion with the understanding of that information by re-
search participants.Conclusion
The empirical findings of this study serve to highlight
the fact that participants display a wide and complex
range of views regarding the use of biological samples in
research. Participants hold strong views on future use,
export and benefit sharing and a consent process that
allows for choice with respect to future use and export
of samples seems prudent. Further research needs to
be conducted to explore the concept of ownership of
samples and benefit sharing in different communities,
both in South Africa and other resource constrained
countries, to improve the consent process and to res-
pect participant autonomy. Community engagement to
clarify understanding of these concepts is critical. How-
ever, the views of researchers must also be elicited and
balanced with participant views in the best interests of
science and society. Research ethics committees have an
important role to play in assessing consent forms and
processes to ensure that information relating to biolo-
gical sample collection and use is stated in a clear and
unambiguous manner.Competing interests
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